| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
796.44(B) |
| Last
Volume: |
1,747,701 |
Avg
Vol: |
3,278,293 |
| 52
Week Range: |
$434.7 - $815.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
505,762 |
1,375,762 |
3,014,918 |
5,975,430 |
| Total Sell Value |
$409,104,400 |
$1,016,789,780 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
10 |
22 |
49 |
89 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lilly Endowment Inc |
10% Owner |
– – • |
2020-06-30 |
4 |
S |
$163.20 |
$27,227,760 |
D/D |
(166,832) |
111,560,304 |
|
11% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-06-29 |
4 |
S |
$163.36 |
$1,867,760 |
D/D |
(11,431) |
111,727,136 |
|
13% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-06-26 |
4 |
S |
$163.01 |
$5,173,404 |
D/D |
(31,737) |
111,738,567 |
|
12% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-06-18 |
4 |
S |
$160.88 |
$8,686,046 |
D/D |
(53,770) |
111,770,304 |
|
18% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-06-17 |
4 |
S |
$160.90 |
$26,019,469 |
D/D |
(161,230) |
111,824,074 |
|
18% |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2020-06-16 |
4 |
AS |
$160.00 |
$2,770,000 |
D/D |
(17,000) |
29,646 |
|
-19% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-06-16 |
4 |
S |
$158.54 |
$34,593,145 |
D/D |
(212,337) |
111,985,304 |
|
19% |
|
| Tai Jackson P |
Director |
– • – |
2020-06-15 |
4 |
A |
$141.52 |
$1,981 |
D/D |
14 |
58,276 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2020-06-05 |
4 |
AS |
$150.00 |
$1,500,000 |
D/D |
(10,000) |
46,646 |
|
-2% |
|
| Tai Jackson P |
Director |
– • – |
2020-05-18 |
4 |
A |
$157.96 |
$1,896 |
D/D |
12 |
58,200 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-04-27 |
4 |
S |
$163.60 |
$2,071,715 |
D/D |
(12,663) |
112,197,641 |
|
6% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-04-24 |
4 |
S |
$161.22 |
$35,743,218 |
D/D |
(220,000) |
112,210,304 |
|
7% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-04-23 |
4 |
S |
$159.36 |
$36,826,587 |
D/D |
(230,000) |
112,430,304 |
|
6% |
|
| Tai Jackson P |
Director |
– • – |
2020-04-20 |
4 |
A |
$157.79 |
$1,893 |
D/D |
12 |
58,188 |
|
- |
|
| Shah Aarti S. |
SVP & CIO |
• – – |
2020-04-14 |
4 |
AS |
$150.00 |
$300,000 |
D/D |
(2,000) |
19,087 |
|
2% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-04-09 |
4 |
S |
$145.14 |
$33,445,542 |
D/D |
(230,000) |
112,660,304 |
|
-5% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-04-07 |
4 |
S |
$142.70 |
$24,676,281 |
D/D |
(172,315) |
112,890,304 |
|
-7% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-04-06 |
4 |
S |
$142.73 |
$2,278,322 |
D/D |
(15,962) |
113,062,619 |
|
-6% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-04-03 |
4 |
S |
$143.04 |
$3,826,493 |
D/D |
(26,723) |
113,078,581 |
|
-6% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-04-02 |
4 |
S |
$140.46 |
$23,374,654 |
D/D |
(166,038) |
113,105,304 |
|
-7% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-03-31 |
4 |
S |
$140.07 |
$5,457,474 |
D/D |
(38,962) |
113,271,342 |
|
-14% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-03-30 |
4 |
S |
$138.16 |
$29,213,559 |
D/D |
(210,000) |
113,310,304 |
|
-14% |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2020-03-30 |
4 |
AS |
$133.82 |
$1,968,434 |
D/D |
(14,657) |
107,415 |
|
14% |
|
| Norton Johna |
Senior VP, Global Quality |
• – – |
2020-03-16 |
4 |
AS |
$131.00 |
$619,237 |
D/D |
(4,727) |
17,674 |
|
23% |
|
| Tai Jackson P |
Director |
– • – |
2020-03-16 |
4 |
A |
$129.38 |
$1,941 |
D/D |
15 |
58,176 |
|
- |
|
1437 Records found
|
|
Page 23 of 58 |
|
|
1.33 (0.16%) 
